Summary
Darunavir is a protease inhibitor (PI) dosed as a single daily tablet. PIs have a high genetic barrier to resistance, but a PI-based single-tablet regimen has not been available. This article presents the results of the week 48 analysis of the Safety and Efficacy of Darunavir/Cobicistat/Emtricitabine/GS-7340 Single Tablet Regimen Versus Cobicistat-Boosted Darunavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate Fixed Dose Combination in HIV-1 Infected, Antiretroviral Treatment Naïve Adults [GS-US-299-0102; NCT01565850].
- Infectious Disease Clinical Trials
- HIV & AIDS
- Infectious Disease Clinical Trials
- Infectious Disease
- HIV & AIDS
- © 2014 MD Conference Express®